Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALVO

Alvotech

May 09 • 04:00PM ET

13.60

Dollar change +0.06
Percentage change 0.44	%

Healthcare • Drug Manufacturers - Specialty & Generic • Luxembourg • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ONEQ STXK FPXE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	80.75%	Shs Outstand	266.82M	Perf Week	-6.27%
Market Cap	3.63B	Forward P/E	232.80	EPS next Y	0.06	Insider Trans	0.00%	Shs Float	51.35M	Perf Month	14.48%
Income	-551.73M	PEG	-	EPS next Q	-0.08	Inst Own	8.52%	Short Float	0.31%	Perf Quarter	-12.20%
Sales	91.43M	P/S	39.69	EPS this Y	79.26%	Inst Trans	8.84%	Short Ratio	0.60	Perf Half Y	57.41%
Book/sh	-3.49	P/B	-	EPS next Y	111.59%	ROA	-62.04%	Short Interest	0.16M	Perf Year	46.71%
Cash/sh	0.04	P/C	325.16	EPS next 5Y	-	ROE	-	52W Range	6.70 - 18.00	Perf YTD	18.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-579.11%	52W High	-24.44%	Beta	-0.04
Dividend TTM	-	Quick Ratio	0.46	Sales past 5Y	3.37%	Gross Margin	-75.93%	52W Low	102.99%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	0.75	EPS Y/Y TTM	-31067.16%	Oper. Margin	-390.24%	RSI (14)	48.51	Volatility	1.47% 2.60%
Employees	1026	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-603.42%	Recom	2.00	Target Price	20.75
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	19.59%	Payout	-	Rel Volume	0.16	Prev Close	13.54
Sales Surprise	-41.77%	EPS Surprise	-2004.76%	Sales Q/Q	123.78%	Earnings	Mar 20 AMC	Avg Volume	267.17K	Price	13.60
SMA20	0.67%	SMA50	-2.16%	SMA200	18.26%	Trades		Volume	41,632	Change	0.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

May-02-24 07:15AM	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
Apr-30-24 04:00AM	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) (Business Wire)
Apr-24-24 04:00AM	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) (GlobeNewswire)
Apr-19-24 06:10AM	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) (GlobeNewswire)
Apr-16-24 05:43PM	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) (Business Wire)
07:41AM	Loading…
Apr-03-24 07:41AM	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
Mar-22-24 04:15PM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire)
Mar-20-24 09:52PM	ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 (InvestorPlace)
04:15PM	Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET (GlobeNewswire)
Feb-29-24 04:05PM	Alvotech Appoints Interim Chief Quality Officer (GlobeNewswire)
Feb-26-24 09:58AM	TEVA Stock Pops 4% as Teva Receives FDA Approval (InvestorPlace) +7.74%
04:25AM	Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share (GlobeNewswire)
Feb-23-24 08:15PM	Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira (Business Wire)
Feb-15-24 06:30AM	Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara (ustekinumab) (GlobeNewswire)
04:00AM	Loading…
Jan-29-24 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jan-22-24 10:03AM	Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates (Zacks)
Jan-19-24 11:30AM	Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 (GlobeNewswire) +15.29%
Jan-10-24 03:30AM	STADA and Alvotech secure approval for Uzpruvo, Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Jan-03-24 03:30AM	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea (aflibercept) (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
Nov-29-23 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria (GlobeNewswire)
Nov-28-23 04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update (GlobeNewswire)
04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update (GlobeNewswire)
Nov-21-23 08:00AM	Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET (GlobeNewswire)
Nov-14-23 07:00AM	Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab) (GlobeNewswire)
Nov-10-23 09:30AM	STADA and Alvotech receive positive CHMP opinion for Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Nov-07-23 08:00AM	Alvotech to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Oct-12-23 04:00AM	Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 (GlobeNewswire)
Oct-05-23 01:21PM	Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland (GlobeNewswire)
08:29AM	Loading…
Oct-03-23 08:29AM	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (Business Wire)
05:00AM	Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Sep-25-23 04:00AM	Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® (GlobeNewswire)
Sep-20-23 04:30AM	Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) (GlobeNewswire)
Sep-11-23 05:00AM	Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 09:30AM	Alvotech Announces Changes to the Leadership Team (GlobeNewswire)
Aug-30-23 04:15PM	Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update (GlobeNewswire)
Aug-29-23 05:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt (GlobeNewswire)
Aug-22-23 09:15AM	Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET (GlobeNewswire)
Jul-31-23 04:00AM	Alvotech Completes $100 Million Convertible Bond Private Placement (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jul-24-23 04:00AM	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership (GlobeNewswire)
Jul-06-23 07:26AM	Should You Exit Alvotech (ALVO)? (Insider Monkey)
Jun-28-23 07:00PM	Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 (GlobeNewswire)
Jun-12-23 07:00AM	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® (Business Wire) -9.51%
May-31-23 05:20AM	Alvotech to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 05:00AM	Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe (GlobeNewswire)
May-19-23 05:00AM	Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update (GlobeNewswire)
May-17-23 05:00AM	Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit (GlobeNewswire) -7.35%
May-15-23 05:00AM	Alvotech Issues Annual Equality Report Covering 2022 (GlobeNewswire)
May-10-23 05:00AM	Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept) (GlobeNewswire)
May-05-23 09:00AM	Alvotech S.A. Annual General Meeting to be held June 6, 2023 (GlobeNewswire)
May-04-23 05:00AM	Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
May-03-23 09:00AM	Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET (GlobeNewswire)
Apr-19-23 05:30PM	Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer (GlobeNewswire)
Apr-13-23 08:45PM	Alvotech Provides Regulatory Update on AVT02 Biologics License Application (GlobeNewswire)
Mar-28-23 05:00AM	Alvotech Provides Update on Corporate Sustainability Framework (GlobeNewswire)
Mar-17-23 09:10AM	Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-01-23 04:30PM	Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-27-23 07:15PM	Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 (GlobeNewswire)
Feb-14-23 04:01PM	Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market (GlobeNewswire)
Feb-10-23 04:01PM	Settlement of Alvotech Private Share Placement Completed (GlobeNewswire)
Feb-09-23 02:30AM	EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
Feb-06-23 04:00AM	Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) (GlobeNewswire)
Jan-24-23 04:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia (GlobeNewswire)
Jan-23-23 03:25AM	Alvotech Completes $137 Million Private Share Placement (GlobeNewswire)
Jan-13-23 04:00AM	Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate (GlobeNewswire) +5.00%
Jan-11-23 04:00AM	Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
Jan-06-23 07:00AM	Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (Business Wire) +6.77%
Dec-22-22 04:00AM	Update on U.S. Regulatory Status of AVT02, Alvotechs Proposed High-Concentration, Interchangeable Biosimilar to Humira® (GlobeNewswire) +17.35%
Dec-16-22 06:45AM	Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT (GlobeNewswire)
06:45AM	Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field (GlobeNewswire)
04:00AM	Alvotech Completes $59.7 Million Private Placement (GlobeNewswire)
Dec-08-22 03:30AM	Alvotech Shares Start Trading on Nasdaq Iceland Main Market (GlobeNewswire) +6.95%
Dec-07-22 04:00AM	Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe (GlobeNewswire) +8.72%
Dec-02-22 10:41AM	Nasdaq Iceland Approves the Request for Trading of Alvotechs Shares on the Main Market (GlobeNewswire)
Dec-01-22 05:00PM	Alvotech Announces Changes to its Leadership Team (GlobeNewswire)
Nov-30-22 02:47PM	Alvotech Submits its Application for Admission of the Companys Shares to Trading on Nasdaq Iceland Main Market (GlobeNewswire)
Nov-16-22 07:27AM	Alvotech Secures Financing Facilities of Approximately $136 Million (GlobeNewswire)
12:00AM	Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update (GlobeNewswire)
Nov-14-22 02:00AM	Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira® (GlobeNewswire) +6.46%
Nov-10-22 04:00AM	Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference (GlobeNewswire) +5.47%
Oct-27-22 05:00PM	Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022 (GlobeNewswire)
Oct-26-22 05:00PM	Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November (GlobeNewswire)
Oct-19-22 08:38PM	Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care (PR Newswire)
Oct-17-22 05:00AM	Alvotechs Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan (GlobeNewswire)
Oct-11-22 05:00PM	Alvotech Appoints Sarah Tanksley as Chief Quality Officer (GlobeNewswire)
Sep-22-22 08:00AM	Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra® (GlobeNewswire) -14.88%
Sep-05-22 05:00AM	Alvotech Reports Update on Initial AVT02 Biologics License Application (GlobeNewswire)
Aug-31-22 05:00PM	Alvotech Reports First Half 2022 Financial Results and Business Update (GlobeNewswire)
Aug-29-22 04:00AM	Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021 (GlobeNewswire)
Aug-25-22 04:00AM	Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire)
Aug-24-22 04:00AM	Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 (GlobeNewswire)
Aug-15-22 04:00AM	Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 (GlobeNewswire) +18.55%
Aug-12-22 04:00AM	Alvotechs Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland (GlobeNewswire)
Aug-08-22 12:17PM	Alvotech (NASDAQ:ALVO): When Will It Breakeven? (Simply Wall St.)
Jul-20-22 08:00AM	Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire) +5.87%
Jul-14-22 08:00AM	Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company (GlobeNewswire)
Jul-07-22 11:28AM	Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea® (GlobeNewswire) -15.76%
Jul-05-22 04:56AM	Increase of share capital and creation of treasury share pool to meet obligations with respect to Warrants issued by Alvotech, the Management Incentive Plan, as well as option to issue shares pursuant to the SEPA facility with Yorkville (GlobeNewswire) -8.48%

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman on August 23, 2021 and is headquartered in Luxembourg.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALVO

Alvotech

Upgrade your FINVIZ experience